Therapeutic Strategies against Ebola Virus Infection

Ching Hsuan Liu, Yee Tung Hu, Shu Hui Wong, Liang Tzung Lin

研究成果: 雜誌貢獻回顧型文獻同行評審

摘要

Since the 2014–2016 epidemic, Ebola virus (EBOV) has spread to several countries and has become a major threat to global health. EBOV is a risk group 4 pathogen, which imposes significant obstacles for the development of countermeasures against the virus. Efforts have been made to develop anti-EBOV immunization and therapeutics, with three vaccines and two antibody-based therapeutics approved in recent years. Nonetheless, the high fatality of Ebola virus disease highlights the need to continuously develop antiviral strategies for the future management of EBOV outbreaks in conjunction with vaccination programs. This review aims to highlight potential EBOV therapeutics and their target(s) of inhibition, serving as a summary of the literature to inform readers of the novel candidates available in the continued search for EBOV antivirals.
原文英語
文章編號579
期刊Viruses
14
發行號3
DOIs
出版狀態已發佈 - 3月 1 2022

ASJC Scopus subject areas

  • 傳染性疾病
  • 病毒學

指紋

深入研究「Therapeutic Strategies against Ebola Virus Infection」主題。共同形成了獨特的指紋。

引用此